Global Cell Viability Assays Market is estimated to be valued at over USD 3.5 billion by 2033 and register a CAGR of over 8.9% from 2025 to 2033.

The growing burden of infectious and chronic diseases, increasing focus on cell-based therapeutic development, and rising demand for cell-based arrays for research activities are important factors that drive the global cell viability assays market further.

According to the statistics provided by the World Health Organization (WHO), chronic diseases are responsible for around 60% of all deaths across the world and it is predicted by WHO that the occurrence of chronic diseases shall increase by around 57% by 2020. These rising incidences of chronic diseases have increased the demand for efficient healthcare infrastructure. Moreover, according to the WHO, nearly 4 out of 5 deaths around the world in 2014, especially in developing countries, occurred due to chronic diseases. According to the Centers for Disease Control and Prevention (CDC), the prevalence of chronic diseases was the main reason for disabilities and deaths in the US in 2017. Around 130 million Americans had at least one chronic disease. Additionally, the increase in demand for healthcare spending is due to the rise of lifestyle-related and age-related chronic diseases.

Cancer and cardiovascular diseases are the new causes of death, especially in developing economies, as a result of rapid urbanization, changing dietary habits, sedentary lifestyles, widespread availability of tobacco products, and rising obesity levels. According to the estimates presented by the CDC, these diseases are the major reason for the death of over 2 million citizens per year in the United States. The growing prevalence of chronic diseases is expected to drive the global cell viability assays market.

Stem Cell Research is Projected to Showcase Remarkable Market Growth Over the Forecast Period

The stem cell research segment is expected to register a high CAGR value over the forecast period, driven by an increase in research and development activities and the funds raised by various organizations for these initiatives. As per the data from the National Institute of Health (NIH), around USD 2000 million were granted for stem cell research and development activities in the fiscal year 2018. The increase in the number of cell-based treatment centers has helped drive stem cell research. Around 580 such centers were established in the US in 2015. All these factors contribute to the growth of the global cell viability assays market.

Global Cell Viability Assays Market Segmentation:

By Product

  • Consumables
    • Reagents
    • Assay Kits
      • Tetrazolium Reduction Assay Kits
        • Mtt Assay Kits
        • Other Tetrazolium Assay Kits
      • Resazurin Cell Viability Assay Kits
      • Calcein-Am Cell Viability Assay Kits
      • Other Assay Kits
    • Microplates
  • Instruments
    • Automated Cell Counters
    • Flow Cytometers
    • Spectrophotometers
    • Cell Imaging and Analysis Systems

By Cell Type

  • Human Cells
  • Animal Cells
  • Microbial Cells

By Application

  • Drug Discovery and Development
  • Basic Research
  • Stem Cell Research
  • Clinical and Diagnostic Applications
  • Other Applications

By End User

  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Hospital and Diagnostic Laboratories
  • Other End Users

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

North America dominates the global landscape due to the presence of leading biotech firms, robust funding ecosystems, and early adoption of advanced assay technologies.

Europe is following closely, driven by expanding research initiatives in Germany, the UK, and France.

Asia-Pacific is projected to grow at the fastest pace, with countries like China, India, and Japan investing heavily in life science infrastructure, CRO growth, and clinical research.

Major Players included in the Cell Viability Assays Market:

  • Thermo Fisher Scientific
  • Merck KGaA
  • Bio-Rad Laboratories
  • GE Healthcare
  • Danaher Corporation
  • Becton
  • Dickinson and Company
  • Promega Corporation
  • Biotium
  • Abcam PLC
  • Creative Bioarray
  • Biotek Instruments
  • PerkinElmer

Recent Developments by Leading Companies

1. Promega Corporation

  • June 2024: Launched the MyGlo™ Reagent Reader—a compact reader designed to streamline 96-well plate luminescence assays (e.g., CellTiter-Glo®), simplifying operation with guided protocols researchandmarkets.com+7industryarc.com+7marketresearchfuture.com+7.

  • CellSensor™ Launch: Rolled out the CellSensor™ Green Fluorescence Live Cell Viability Assay, optimized for high-throughput fluorescence imaging

2. Thermo Fisher Scientific

  • October 2023: Deployed Genedrive platform, a fully automated cellular testing system aimed at high-throughput drug screening.

  • Nov 2021: Partnered with Cellenion to integrate single-cell proteomic reagents and Orbitrap mass spectrometry into multiparametric cellular workflows.

  • Acquisition: Absorbed Pheno Therapeutics to bolster high-throughput antibody screening capabilities

3. PerkinElmer Inc.

  • September 2022: Introduced the Cellaca PLX Image Cytometry System aimed at automated phenotyping for CAR-T and cell therapy analytics.

  • May 2021: Acquired Nexcelom Bioscience to strengthen its live-cell and image cytometry portfolio

Objectives of the Study:

  • To provide with an exhaustive analysis on the global Cell Viability Assays Market By Product, By Cell Type, By Application, By End User and By Region
  • To provide comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions (along with countries)—North America, Asia Pacific, Europe, Latin America, The Middle East and Africa
  • To record, evaluate, and create a competitive landscape mapping-product launches, technological advancements, mergers, and expansions
  • Profiling of companies to evaluate their market shares, strategies, financials and core competencies

Get unlimited analyst support and customise this study further to your requirements, contact sales@futurewiseresearch.com